This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
European Journal of Nuclear Medicine and Molecular Imaging Open Access 12 October 2023
-
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years
Annals of Hematology Open Access 12 February 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
18 December 2018
In the version of this article initially published, the descriptions of Actinium Pharmaceuticals' Iomab-B and Nordic Nanovector's 177Lu-lilotomab satetraxetan (Betalutin) were reversed. Iomab-B uses iodine-131 to destroy the bone marrow ahead of stem cell transplantation and Betalutin directs lutetium-177 to CD45-expressing B cells in follicular lymphoma. The error has been corrected in the HTML and PDF versions of the article.
18 January 2019
In the version of this article initially published, Betalutin was described as directing a radioisotope to CD45-expressing B cells; in fact, it directs it to CD37-expressing B cells. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Radioactive drugs emerge from the shadows to storm the market. Nat Biotechnol 36, 1125–1127 (2018). https://doi.org/10.1038/nbt1218-1125
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1218-1125
This article is cited by
-
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
European Journal of Nuclear Medicine and Molecular Imaging (2024)
-
Clinical translation of radiotheranostics for precision oncology
Nature Reviews Bioengineering (2023)
-
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years
Annals of Hematology (2022)
-
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Nature Reviews Drug Discovery (2020)